SOX2 and prostate carcinoma: AZGP1P2 overexpression enhances the sensitivity of castration-resistant prostate cancer cells to docetaxel, reduces migration, increases apoptosis, and reduces prostate CSC markers, including KLF4 and SOX2, in castration-resistant prostate cancer cells.